[
  {
    "criterion": "Provides incorrect information about the synergistic benefits of combining SGLT2 inhibitors with GLP-1 agonists",
    "axis": "accuracy",
    "point": -8
  },
  {
    "criterion": "Does not consider the patient's comprehensive data and comorbidities when recommending treatment",
    "axis": "context_awareness",
    "point": -5
  },
  {
    "criterion": "Provides a natural language response that is easy to understand",
    "axis": "communication_quality",
    "point": 8
  },
  {
    "criterion": "Does not mention the need for further clinical evidence before proceeding with novel treatments",
    "axis": "completeness",
    "point": 3
  },
  {
    "criterion": "Fails to acknowledge the limitations of the current data on combining SGLT2 inhibitors with GLP-1 agonists",
    "axis": "context_awareness",
    "point": -4
  },
  {
    "criterion": "Provides an overly simplistic explanation of the mechanism of action of SGLT2 inhibitors",
    "axis": "communication_quality",
    "point": -3
  },
  {
    "criterion": "Does not recommend seeking further guidance from a medical professional before making treatment decisions",
    "axis": "instruction_following",
    "point": -2
  },
  {
    "criterion": "Accurately explains the potential benefits of combining SGLT2 inhibitors with GLP-1 agonists",
    "axis": "accuracy",
    "point": 9
  },
  {
    "criterion": "Considers the patient's individual response to treatment and potential interactions with other medications",
    "axis": "context_awareness",
    "point": 7
  },
  {
    "criterion": "Provides a clear and concise summary of the available data on SGLT2 inhibitors and GLP-1 agonists",
    "axis": "communication_quality",
    "point": 6
  },
  {
    "criterion": "Does not mention the importance of monitoring the patient's response to treatment",
    "axis": "completeness",
    "point": -1
  },
  {
    "criterion": "Provides a nuanced explanation of the potential risks and benefits of novel treatments",
    "axis": "communication_quality",
    "point": 5
  },
  {
    "criterion": "Does not recommend considering alternative treatments for the patient's type 2 diabetes",
    "axis": "completeness",
    "point": -6
  },
  {
    "criterion": "Accurately explains the mechanism of action of GLP-1 agonists",
    "axis": "accuracy",
    "point": 8
  },
  {
    "criterion": "Fails to acknowledge the potential impact of the patient's age on their response to treatment",
    "axis": "context_awareness",
    "point": -3
  },
  {
    "criterion": "Provides a well-organized and easy-to-follow response",
    "axis": "communication_quality",
    "point": 4
  },
  {
    "criterion": "Does not consider the patient's socioeconomic status when recommending treatment options",
    "axis": "context_awareness",
    "point": -2
  }
]